文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-6R-aza-5-MTHF:一种可用于筛选FRα靶向治疗患者的PET示踪剂

Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy.
PubMed 文献 · J Nucl Med · 2021-01-15

本研究旨在识别对叶酸受体α(FRα)具有选择性的PET示踪剂,以筛选可能从FRα靶向治疗中获益的患者。研究比较了18F-aza-5-甲基四氢叶酸(MTHF)的6R和6S异构体与18F-AzaFol对FRα和FRβ的结合特性,并通过细胞摄取、亲和力测定、放射自显影、生物分布及PET/CT显像进行评估。结果显示18F-6R-aza-5-MTHF对FRα具有高选择性,在FRα阳性肿瘤中摄取高而在FRβ阳性炎症细胞中摄取低,有望用于临床转化。

要点

  • 18F-6R-aza-5-MTHF对FRα的亲和力较FRβ高约43倍(IC50 1.8 nM vs 77 nM)。
  • 该示踪剂在FRα阳性RT16肿瘤中摄取达81%±20% IA/g(注射后1小时),而在FRβ阳性D4肿瘤中仅7.3%±2.1% IA/g。
  • 18F-6S-aza-5-MTHF和18F-AzaFol对FRα和FRβ均无选择性,两者在两种细胞系中摄取相似。

核心结论

  • 18F-6R-aza-5-MTHF对FRα具有选择性,而18F-6S-aza-5-MTHF和18F-AzaFol对FRα无选择性。
  • 18F-6R-aza-5-MTHF的组织分布特征使其有望用于临床转化,以检测FRα阳性肿瘤并避免在FRβ表达的炎症细胞中蓄积。

研究设计与样本

  • 研究使用FRα转染的RT16和FRβ转染的D4 CHO细胞评估FR选择性,并测定放射性示踪剂的细胞摄取和非放射性类似物的受体结合亲和力。
  • 对RT16和D4组织切片进行18F-叶酸示踪剂的体外放射自显影。
  • 在荷RT16和D4异种移植瘤的小鼠中进行生物分布研究和PET/CT显像。

主要发现

  • 18F-6R-aza-5-MTHF在RT16细胞中的摄取为62%±10%(加入活度),在D4细胞中为5%±2%。
  • 18F-6R-aza-5-MTHF对FRα的IC50为1.8±0.1 nM,对FRβ的IC50为77±27 nM,亲和力相差约43倍。
  • 18F-6S-aza-5-MTHF和18F-AzaFol在两种细胞系中摄取相似(52%-70%),对FRα的IC50分别为2.1±0.4 nM和0.6±0.3 nM,对FRβ的IC50分别为0.8±0.2 nM和0.3±0.1 nM。
  • 18F-6R-aza-5-MTHF的放射自显影信号在RT16组织切片中比D4切片强11倍。
  • 生物分布显示18F-6R-aza-5-MTHF在RT16异种移植瘤中摄取为81%±20% IA/g(注射后1小时),在D4异种移植瘤中为7.3%±2.1% IA/g(注射后1小时),PET显像可可视化。

临床怎么用

  • 18F-6R-aza-5-MTHF有望作为PET示踪剂,用于筛选可能从FRα靶向治疗中获益的患者。
  • 该示踪剂可检测FRα阳性肿瘤,同时避免在FRβ表达的炎症细胞中蓄积,从而提高诊断特异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to identify a folate receptor-α (FRα)-selective PET agent potentially suitable for the selection of patients who might profit from FRα-targeted therapies. The 6R and 6S isomers of 18F-aza-5-methyltetrahydrofolate (MTHF) were assessed regarding their binding to FRα and FRβ, expressed on cancer and inflammatory cells, respectively, and compared with 18F-AzaFol, the folic acid-based analog. Methods: FR selectivity was investigated using FRα-transfected (RT16) and FRβ-transfected (D4) CHO cells. The cell uptake of 18F-folate tracers was investigated, and receptor-binding affinities were determined with the nonradioactive analogs. In vitro autoradiography of the 18F-folate tracers was performed using RT16 and D4 tissue sections. Biodistribution studies and PET/CT imaging of the radiotracers were performed on mice bearing RT16 and D4 xenografts. Results: The uptake of 18F-6R-aza-5-MTHF was high when using RT16 cells (62% ± 10% of added activity) but much lower when using D4 cells (5% ± 2%). The FRα selectivity of 18F-6R-aza-5-MTHF was further demonstrated by its approximately 43-fold higher binding affinity to FRα (half-maximal inhibitory concentration [IC50], 1.8 ± 0.1 nM) than to FRβ (IC50, 77 ± 27 nM). The uptake of 18F-6S-aza-5-MTHF and 18F-AzaFol was equal in both cell lines (52%-70%), with similar affinities to FRα (IC50, 2.1 ± 0.4 nM and 0.6 ± 0.3 nM, respectively) and FRβ (0.8 ± 0.2 nM and 0.3 ± 0.1 nM, respectively). The autoradiography signal obtained with 18F-6R-aza-5-MTHF was 11-fold more intense for RT16 than for D4 tissue sections. Biodistribution data showed high uptake of 18F-6R-aza-5-MTHF in RT16 xenografts (81% ± 20% injected activity per gram [IA]/g 1 h after injection) but significantly lower accumulation in D4 xenografts (7.3% ± 2.1% IA/g 1 h after injection), which was also visualized using PET. The uptake of 18F-6S-aza-5-MTHF and 18F-AzaFol was similar in RT16 (53% ± 10% IA/g and 45% ± 2% IA/g, respectively) and D4 xenografts (77% ± 10% IA/g and 52% ± 7% IA/g, respectively). Conclusion: This study demonstrated FRα selectivity for 18F-6R-aza-5-MTHF but not for 18F-6S-aza-5-MTHF or 18F-AzaFol. This characteristic, together with its favorable tissue distribution, makes 18F-6R-aza-5-MTHF attractive for clinical translation to enable detection of FRα-positive cancer while preventing undesired accumulation in FRβ-expressing inflammatory cells.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Guzik P, Fang HY, Deberle LM, et al. Identification of a PET Radiotracer for Imaging of the Folate Receptor-α: A Potential Tool to Select Patients for Targeted Tumor Therapy. J Nucl Med. 2021. PMID: 33452043. doi:10.2967/jnumed.120.255760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。